Figure 5.

PDXs Derived from Vemurafenib-Resistant Melanomas Harbor a Plethora of Established Clinical Resistance Mechanisms

(A) Immunoblotting for p-ERK and p-AKT to detect reactivation of the MAPK pathway and/or the PI3K/AKT pathway in the post-vemurafenib PDXs. Vinculin was used as a loading control.

(B) Immunoblotting to detect previously described resistance mechanisms in post-vemurafenib PDXs. Vinculin was used as a loading control.

(C) Analysis of BRAF^T1799A amplification by qPCR on gDNA of all post-vemurafenib PDXs is shown.

(D) DNA copy-number profiles revealed amplification of the region containing MITF in two independent PDXs.